CRIS Current Research Information System

TANI, MONICA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.655
AS - Asia 2.321
EU - Europa 1.745
AF - Africa 143
SA - Sud America 92
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 6.962
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.614
VN - Vietnam 787
SG - Singapore 556
CN - Cina 539
GB - Regno Unito 447
SE - Svezia 337
DE - Germania 222
IT - Italia 185
HK - Hong Kong 146
FR - Francia 110
UA - Ucraina 96
IN - India 83
RU - Federazione Russa 77
IE - Irlanda 67
BR - Brasile 56
CI - Costa d'Avorio 45
JO - Giordania 40
JP - Giappone 38
ZA - Sudafrica 37
NL - Olanda 34
HR - Croazia 31
FI - Finlandia 28
KR - Corea 26
TG - Togo 26
EE - Estonia 25
CA - Canada 23
CH - Svizzera 20
PH - Filippine 19
BE - Belgio 16
AR - Argentina 15
IR - Iran 12
NG - Nigeria 12
PL - Polonia 12
TW - Taiwan 11
ES - Italia 10
TR - Turchia 10
BG - Bulgaria 9
SC - Seychelles 9
TH - Thailandia 9
BD - Bangladesh 8
EC - Ecuador 8
ID - Indonesia 8
MX - Messico 8
GR - Grecia 6
UZ - Uzbekistan 5
AT - Austria 4
IQ - Iraq 4
MA - Marocco 4
TN - Tunisia 4
CL - Cile 3
IL - Israele 3
KE - Kenya 3
LB - Libano 3
SA - Arabia Saudita 3
VE - Venezuela 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
AU - Australia 2
BO - Bolivia 2
CO - Colombia 2
LK - Sri Lanka 2
MY - Malesia 2
NZ - Nuova Zelanda 2
PA - Panama 2
PK - Pakistan 2
PR - Porto Rico 2
PY - Paraguay 2
RO - Romania 2
CM - Camerun 1
CR - Costa Rica 1
CY - Cipro 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
ET - Etiopia 1
GT - Guatemala 1
HN - Honduras 1
HT - Haiti 1
HU - Ungheria 1
KN - Saint Kitts e Nevis 1
KZ - Kazakistan 1
LT - Lituania 1
NO - Norvegia 1
PS - Palestinian Territory 1
PT - Portogallo 1
RS - Serbia 1
SI - Slovenia 1
UY - Uruguay 1
Totale 6.962
Salva come PNG Salva come JPEG
Città #
Singapore 397
Southend 382
Fairfield 253
Ashburn 243
Chandler 219
Houston 169
Ho Chi Minh City 156
Ann Arbor 155
Hanoi 135
Hong Kong 135
Woodbridge 132
Seattle 119
San Jose 114
Wilmington 107
Cambridge 89
Beijing 82
Dong Ket 82
Santa Clara 79
Hefei 76
Princeton 76
Dublin 67
Jacksonville 66
Boardman 63
Los Angeles 54
New York 46
Abidjan 45
Nanjing 43
Lauterbourg 41
Amman 40
Westminster 36
Turin 35
Padova 34
Tokyo 27
Lomé 26
Berlin 24
Da Nang 24
Helsinki 23
Munich 22
Seoul 22
Buffalo 21
Haiphong 20
Jinan 19
Saint Petersburg 19
Changsha 18
Frankfurt am Main 17
Shenyang 17
Bologna 16
Milan 15
Nanchang 14
San Diego 14
Guangzhou 13
Redwood City 13
Abeokuta 12
Bremen 12
Brussels 12
Jiaxing 12
Bern 11
Can Tho 11
Florence 10
Mülheim 10
Phoenix 10
São Paulo 10
Zhengzhou 10
Chicago 9
Falkenstein 9
Hangzhou 9
Hải Dương 9
Sofia 9
Hebei 8
Norwalk 8
Tianjin 8
Warsaw 8
Dearborn 7
London 7
Taizhou 7
Wuhan 7
Zanjan 7
Biên Hòa 6
Dallas 6
Düsseldorf 6
Falls Church 6
Quito 6
Quận Bình Thạnh 6
San Francisco 6
Amsterdam 5
Bắc Ninh 5
Ha Long 5
Izumo 5
Johannesburg 5
Mahé 5
Redmond 5
Redondo Beach 5
Rome 5
Ankara 4
Denver 4
Harbin 4
Jakarta 4
Kunming 4
Lausanne 4
Madrid 4
Totale 4.501
Salva come PNG Salva come JPEG
Nome #
Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. 263
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. 253
Effectiveness of Fludarabine, Idarubicin and Cyclophosphade (FLUIC) Combination Regimen for Young Patients with Untreated Non-Follicular Low-Grade Non-Hodgkin’s Lymphoma. 248
18 F-FDG PET in malignant lymphoma: significance of positive findings 244
A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. 244
A phase 2 trial of fludarabine and mitoxantrone chemoterapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma 234
Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. 229
Value of oxaliplatin treatment in heavily pretreated patients with non-Hodgkin's lymphoma. 220
18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma. 216
High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experience 212
Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. 208
Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. 208
Interim positron emission tomography response-adapted therapy in advanced-stage hodgkin lymphoma: Final results of the phase II part of the HD0801 study 203
Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma 202
Patologic IL 17 Producing Helper T Cells In Acute Myeloid Leukemia Patients 200
Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. 194
Discordant response to chemotherapy: An unusual pattern of fluoro-deoxy-D-glucose uptake in heavily pre-treated lymphoma patients 193
Phase II trial of temozolomide in patients with pretreated cutaneous T-cell lymphoma. 190
Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice 172
Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. 171
Role of anemia in survival of patients with elderly aggressive non-Hodgkin's lymphoma after chemotherapy. 170
Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma 169
Late FDG PET normalization after radioimmunotherapy in a patient with non-Hodgkin lymphoma. 165
Early relapse in a patient with Hodgkin's disease and negative interim FDG-PET. 163
Gemcitabine as frontline treatment for cutaneous T-cell lymphoma. 162
Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study) 162
FDG PET and 90Y ibritumomab tiuxetan in patients with follicular lymphoma. 161
Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. 160
Efficacy and safety of oral fludarabine/cyclophosphamide regimen in previously treated indolent lymphomas. 159
Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma. 155
Clinical significance of axillary findings in patients with lymphoma during follow-up with 18F-fluorodeoxyglucose-PET. 153
Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine 149
Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). 146
FDG-PET in the serial assessment of patinets with lymphoma in complete remission 140
Safety and Efficacy of Single-Agent Bendamustine After Failure of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin's Lymphoma: Experience With 27 Patients. 137
Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia. 134
Pixantrone as bridging therapy to allogeneic transplantation or in chimeric antigen receptor T‐cell pathway in patients with diffuse large B‐cell lymphoma 82
Erratum: Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients (Haematologica (2005) 90, (225-231). 79
Lenalidomide plus rituximab for the initial treatment of elderly frail patients with DLBCL: the FIL_ReRi Phase 2 Study 77
Gemcitabine 28
Totale 7.055
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.787
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.787
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021202 0 0 0 0 0 0 0 0 0 0 47 155
2021/2022916 194 21 65 117 57 47 17 48 21 47 180 102
2022/2023948 107 108 54 115 69 84 20 37 211 29 72 42
2023/2024195 13 44 8 27 15 51 5 10 5 8 2 7
2024/2025856 28 168 75 47 162 47 55 11 4 67 18 174
2025/20261.988 160 279 161 110 243 137 145 46 467 162 78 0
Totale 7.055